Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2007

View Archived Issues

Positive preclinical profile of the CRF1 antagonist MTIP in animal models of alcoholism

Nycomed restructures following Altana Pharma acquisition

MerLion and Merck Banyu enter new drug discovery alliance

VASTox acquires DanioLabs and Dextra Laboratories

Pain Therapeutics in-licenses new technology for treatment of hemophilia

Results from phase I study of AEOL-10150

Dll4 as a novel target for antiangiogenic drugs

Affirmative preclinical profile set BEZ-235 for clinical evaluation

Nilvadipine show positive preliminary results in Alzheimer's

Quinvaxem vaccinations in Ethiopia

Amira raises funding to advance drug candidates through proof of concept

New WHO guidance on pneumococcal vaccines in developing countries

NovaDel Pharma outlines 2007 goals

Hana Biosciences provides pipeline update

New treatment options for metabolic disorders are disclosed in patent literature

Novel therapeutic strategies for the treatment of infection described in recent patents

Synosis Therapeutics changes name to Synosia Therapeutics

Eisai granted rights to Eril in Korea

Genta expects negative European opinion for Genasense in advanced melanoma

EAU's new guidelines recommend Sutent in first-line metastatic RCC

Revlimid recommended for approval in E.U. for multiple myeloma

Altargo recommended for E.U. approval

E.U. recommends approval of Herceptin for new breast cancer indication

Januvia approved in E.U. for type 2 diabetes

Roche files sNDA for XELOX in metastatic colorectal cancer

A-620223 a potent inhibitor of poly(ADP-ribose) polymerase

GlaxoSmithKline identifies GSK-983 as potential human papillomavirus treatment

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026